Drp1 (Dynamin Related Protein 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dynamin-related protein 1 (DRP1), encoded by the DNM1L gene, is a large cytosolic GTPase (~80 kDa) that serves as the primary mediator of mitochondrial fission in mammalian cells. DRP1 is recruited from the cytosol to the outer mitochondrial membrane, where it oligomerizes into ring-like structures that constrict and sever mitochondria through GTP hydrolysis. In neurons, DRP1-mediated fission is essential for mitochondrial distribution to energy-demanding regions such as synapses, for mitochondrial quality control through mitophagy, and for apoptosis.
Dysregulated DRP1 activity — typically excessive activation leading to pathological mitochondrial fragmentation — is a convergent feature of Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS. Increased DRP1 levels and enhanced GTPase activity have been documented in postmortem AD brain tissue, and DRP1 interaction with disease proteins (mutant huntingtin, hyperphosphorylated tau promotes mitochondrial fragmentation and neuronal dysfunction. These findings have made DRP1 an attractive, though challenging, therapeutic target (Reddy et al., 2011).
DRP1 is a dynamin superfamily GTPase with four functional domains:
| Domain | Residues (approx.) | Function |
|---|---|---|
| GTPase domain | 1–335 | Binds and hydrolyzes GTP; drives conformational change for membrane constriction |
| Middle domain (MD) | 336–502 | Critical for self-assembly into higher-order oligomers; mediates inter-rung contacts in the ring structure |
| GTPase effector domain (GED) | 637–736 | Stimulates GTPase activity upon oligomerization; folds back to contact the GTPase domain |
| Variable domain (VD/B-insert) | 503–636 | Brain-specific alternative splicing; mediates lipid binding and membrane interactions; unique to DRP1 (not found in classical dynamins) |
Unlike classical dynamins, DRP1 lacks a pleckstrin homology (PH) domain and does not directly bind lipid membranes with high affinity. Instead, it requires receptor proteins on the outer mitochondrial membrane for recruitment.
DRP1 assembles into contractile rings through a hierarchical oligomerization process:
Cryo-EM structures of the DRP1 oligomeric ring have revealed the molecular contacts underlying ring assembly and constriction, showing that the middle domain and GED form the inter-rung interfaces critical for cooperative GTPase activity.
DRP1 activity is tightly regulated by a network of post-translational modifications:
| Modification | Site | Enzyme | Effect |
|---|---|---|---|
| Phosphorylation | Ser616 | Cdk1/cyclin B, ERK1/2, CaMKII | Activating — promotes GTPase activity and mitochondrial recruitment |
| Phosphorylation | Ser637 | PKA, CaMKIα | Inhibiting — reduces GTPase activity; sequestration in cytosol |
| Dephosphorylation | Ser637 | Calcineurin (PP2B) | Activating — removes inhibitory phosphorylation; calcium-dependent |
| SUMOylation | Multiple Lys | SUMO1/Ubc9 | Stabilizes DRP1 at mitochondria; promotes fission |
| deSUMOylation | Multiple Lys | SENP5 | Promotes DRP1 release from mitochondria |
| S-nitrosylation | Cys644 | NO | Activating — promotes dimerization and GTPase activity; elevated in AD brain |
| O-GlcNAcylation | Thr585, Thr586 | OGT | Activating; increased under high glucose conditions |
| Ubiquitination | Multiple Lys | MARCH5, Parkin | Proteasomal degradation; quality control |
| Acetylation | Lys642 | p300 | Promotes mitochondrial recruitment |
The balance between Ser616 phosphorylation (activating) and Ser637 phosphorylation (inhibiting) is a critical determinant of DRP1 activity and is disrupted in neurodegenerative diseases.
DRP1 is recruited to the outer mitochondrial membrane by four receptor proteins:
| Receptor | Mechanism | Disease Relevance |
|---|---|---|
| MFF (Mitochondrial Fission Factor) | Primary receptor for physiological fission; directly binds DRP1 | MFF mutations cause encephalopathy with optic atrophy |
| MiD49 (MIEF2) | Recruits and sequesters DRP1 in an inactive state | Expressed in most tissues |
| MiD51 (MIEF1) | Similar to MiD49; binds ADP as cofactor | Heart and brain expression |
| FIS1 (Fission 1) | Primarily involved in stress-induced/pathological fission; interacts with DRP1 under disease conditions | Key target for P110 peptide inhibitor |
The distinction between MFF-mediated physiological fission and FIS1-mediated pathological fission has therapeutic implications: selectively blocking the DRP1-FIS1 interaction may reduce disease-associated fragmentation while preserving normal mitochondrial dynamics.
neurons contain thousands of mitochondria that must be precisely positioned at sites of high energy demand:
DRP1-mediated fission generates smaller, more mobile mitochondria that can be transported by kinesin/dynein motors along microtubules to distal sites. Without DRP1, neurons develop elongated, poorly distributed mitochondrial networks that cannot adequately supply synaptic energy demands.
DRP1 fission is essential for mitochondrial quality control:
Multiple alterations in DRP1 have been documented in AD:
These converging insults produce excessive mitochondrial fragmentation in AD neurons, resulting in impaired bioenergetics, increased reactive oxygen species, calcium dysregulation, and ultimately synaptic dysfunction and neuronal death.
Recent studies (2024) demonstrate that acutely blocking excessive DRP1-mediated mitochondrial fission after traumatic brain injury prevents chronic neurodegeneration, further validating DRP1 as a neuroprotective target.
| Drug/Compound | Mechanism | Stage | Key Findings |
|---|---|---|---|
| Mdivi-1 | Originally described as DRP1 GTPase inhibitor | Preclinical | Neuroprotective in multiple models; however, recent studies show effects may be due to Complex I inhibition rather than direct DRP1 inhibition; significant off-target effects |
| P110 | Peptide inhibitor blocking DRP1-FIS1 interaction | Preclinical | Selectively inhibits pathological (FIS1-mediated) fission without blocking physiological fission; reduces pathology in AD, PD, HD, and ALS models; brain-penetrant |
| Dynasore | Pan-dynamin inhibitor | Research tool | Too non-specific for therapeutic use |
| SC9 | Novel small molecule DRP1 inhibitor | Early preclinical | More selective than Mdivi-1; structure-based design |
P110 represents the most promising DRP1-targeting strategy because it specifically blocks the DRP1-FIS1 interaction that drives pathological fission, while preserving MFF-mediated physiological fission. P110 was found to bind to a switch I-adjacent groove (SWAG) on DRP1, an allosteric site distinct from the GTPase active site (Joshi et al., 2023). P110 has demonstrated neuroprotection in:
Given the complexity of mitochondrial dysfunction in neurodegeneration, combination approaches are being explored:
The study of Drp1 (Dynamin Related Protein 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.